Literature DB >> 30509108

Circ-ITCH regulates triple-negative breast cancer progression through the Wnt/β-catenin pathway.

S T Wang1, L B Liu1, X M Li1, Y F Wang1, P J Xie2, Q Li1, R Wang1, Q Wei1, Y H Kang1, R Meng1, X H Feng1.   

Abstract

Recent studies indicate that circular RNA (circRNA) is involved in tumorigenesis, but its role in triple-negative breast cancer (TNBC) remains largely unknown. In this study, we characterized the role of circ-ITCH in TNBC and found that circ-ITCH was significantly down-regulated in TNBC tissues and cell lines and closely associated with poor prognosis. We therefore constructed the MDA-MB-231 and BT-549 TNBC cell lines stably expressing circ-ITCH by lentiviral vectors to determine its underlying mechanisms in TNBC progression. Most importantly, over-expression of circ-ITCH remarkably inhibited TNBC proliferation, invasion and metastasis both in vitro and in vivo. Mechanistically, we found that circ-ITCH acts as a sponge for miR-214 and miR-17 to increase expression of its ITCH linear isoform, thereby inactivating Wnt/β-catenin signaling. Our combined results show for the first time that circ-ITCH is a tumor suppressor, a promising prognostic biomarker in TNBC and that its restoration could well be a successful strategy in TNBC.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30509108     DOI: 10.4149/neo_2018_180710N460

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  32 in total

Review 1.  Roles of circular RNA in breast cancer: present and future.

Authors:  Zehuan Li; Zhanghan Chen; Guohua Hu; Ying Jiang
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

Review 2.  The roles of E3 ligases in Hepatocellular carcinoma.

Authors:  Zongdong Yu; Hong Li; Jie Zhu; Haibiao Wang; Xiaofeng Jin
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

Review 3.  The functional significance and cross-talk of non-coding RNAs in triple negative and quadruple negative breast cancer.

Authors:  Utpalendu Paul; Satarupa Banerjee
Journal:  Mol Biol Rep       Date:  2022-03-02       Impact factor: 2.742

Review 4.  Circular RNAs as novel biomarkers in triple-negative breast cancer: a systematic review.

Authors:  Zahra Foruzandeh; Davood Ghavi Dorabadi; Farzaneh Sadeghi; Fatemeh Zeinali-Sehrig; Mohammad Zaefizadeh; Yazdan Rahmati; Mohammad Reza Alivand
Journal:  Mol Biol Rep       Date:  2022-05-10       Impact factor: 2.742

5.  The Regulation Network and Clinical Significance of Circular RNAs in Breast Cancer.

Authors:  Juan Xu; Xiyi Chen; Yu Sun; Yaqian Shi; Fang Teng; Mingming Lv; Chen Liu; Xuemei Jia
Journal:  Front Oncol       Date:  2021-07-09       Impact factor: 6.244

6.  Circular RNA CircITCH (has-circ-0001141) suppresses hepatocellular carcinoma (HCC) progression by sponging miR-184.

Authors:  Xuan Guo; Ziying Wang; Xue Deng; Yantong Lu; Xuhui Huang; Juze Lin; Xiaohe Lan; Qiao Su; Changjun Wang
Journal:  Cell Cycle       Date:  2022-04-09       Impact factor: 5.173

Review 7.  Current Status of Functional Studies on Circular RNAs in Bladder Cancer and their Potential Role as Diagnostic and Prognostic Biomarkers: A Review.

Authors:  Liang Cong; Qiwei Yang; Chunmei Hu; Qiong Yu; Shuhong Hao; Dongfu Li
Journal:  Med Sci Monit       Date:  2019-05-09

Review 8.  The Emerging Role of Circ-SHPRH in Cancer.

Authors:  Xinyue Ju; Yan Tang; Rongfeng Qu; Shuhong Hao
Journal:  Onco Targets Ther       Date:  2021-07-13       Impact factor: 4.147

Review 9.  Functional roles of circular RNAs during epithelial-to-mesenchymal transition.

Authors:  Bing-Qing Shang; Min-Le Li; Hao-Yu Quan; Ping-Fu Hou; Zhong-Wei Li; Su-Fang Chu; Jun-Nian Zheng; Jin Bai
Journal:  Mol Cancer       Date:  2019-09-16       Impact factor: 27.401

10.  circHIPK3 (hsa_circ_0000284) Promotes Proliferation, Migration and Invasion of Breast Cancer Cells via miR-326.

Authors:  Liqiang Qi; Bo Sun; Beibei Yang; Su Lu
Journal:  Onco Targets Ther       Date:  2021-06-09       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.